Proactive Investors - Run By Investors For Investors
Why invest in CLIN?

Clinigen fires on all fronts in strong half year

The company's update reveals a company in rude health
Clinigen fires on all fronts in strong half year
Clinigen seems to have found the formula for financial success.

Clinigen Group PLC (LON:CLIN) is firing on all cylinders as organic growth, a  new acquisition and currency movements all combine favourably.

Gross profit in the half year to December was up by 34% with the contributions of recent acquisition Link Healthcare and the clinical trial arm leading the way said Shaun Chilton, chief executive.

“Link Healthcare has achieved an outstanding performance, demonstrating the value of its acquisition by the Group, “ he said.

Link’s pro forma growth was 35% above a year ago and attributed to strong organic demand across all geographies allied to gains from the dip in the pound.

“Among the other divisions, Clinical Trials Services has again delivered a standout performance," said Chilton.  

"Managed Access and Specialty Pharma also delivered strong growth,” he added.

Going forward, the speciality pharma division expects to see the benefits of the ethyol licence transfer to US partner Cumberland in the second half while acquisition Totect will start to generate sales in the fourth quarter.

Talks over the lifting the restrictions on using Cardioxane also are moving forward.

“We are trading in line with our expectations and are well positioned to deliver good performances across all divisions in H2,” Chilton added.



Clinigen is essentially four different companies under one roof, although there are synergies between the component parts.

Clinical trial services essentially does what it says on the tin – it supplies drugs for clinical trials.

There is an ethical dimension to Clinigen in that it provides managed access and global access programmes for drugs, so it might find and distribute medicines for compassionate use.

Global access allows a medicine not yet commercially available, or is experiencing temporary supply problems, to be distributed to those in need.

Finally, Clinigen has a niche drugs arm (speciality pharma) for products that don’t fit into the portfolio of mainstream pharmaceutical companies. This business provided the strongest growth in the first half.


What the brokers say

N+1 Singer

“A solid first half update with the promise of more good news to come.”

No changes to forecasts of sales in the year to June 2017 of £385mln (£340mln) and profits of £60mln (£49mln) or the 895p target price.

Peel Hunt

Clinigen trades on 18  times next year’s earnings offering 9%/15% three year top line and earnings growth.

Pharma peers trade on 21 times for similar sales and profits profiles, so it is ‘buy’ for the broker with a 1,000p price target.


Register here to be notified of future CLIN Company articles
View full CLIN profile

Clinigen Group PLC Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
March 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use